Shandong New Time Pharmaceutical Co., LTD
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-36
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO0%
Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Shandong New Time Pharmaceutical Co., LTD on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Phase III NCT06819774 |
P3 | Recruiting | Acute Urticaria | 284 | 2025-08 |
| CAPEOX NCT06722950 |
P2 | Not yet recruiting | Colorectal Adenoma | 120 | 2026-12 |
| Vonorasan fumarate injection1 NCT06783257 |
P2 | Not yet recruiting | Peptic Ulcer Bleeding | 150 | 2027-02 |
| Valsartan Oral Solution NCT06863987 |
P3 | Enrolling by invitation | Essential Hypertension | 342 | 2027-12 |
| F520 combined with chemotherapy NCT07761429 |
P2/3 | Recruiting | Cancer of Unknown Primary Site | 402 | 2027-12-30 |
| F182112+P NCT07312188 |
P2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 90 | 2028-05-20 |
| F027 NCT07046273 |
P3 | Not yet recruiting | Type 2 Diabetes (T2DM) | 496 | 2028-08-01 |
| Rulonilimab NCT06755515 |
P2/3 | Enrolling by invitation | Cervical Cancer | 510 | 2028-09 |
| F182112 single-agent NCT07579234 |
P3 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 261 | 2029-01-25 |